Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
grade C 63.51 1.05% 0.66
BHVN closed up 1.05 percent on Friday, September 18, 2020, on 1.6 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical BHVN trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 1.05%
Bollinger Band Squeeze Range Contraction 1.05%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.03%
Spinning Top Other 1.03%
Bollinger Band Squeeze Range Contraction 1.03%
Inside Day Range Contraction 1.03%
Older End-of-Day Gignals for BHVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Neurodegenerative Diseases Chemical Entity Riluzole

Is BHVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 78.75
52 Week Low 26.56
Average Volume 484,242
200-Day Moving Average 54.51
50-Day Moving Average 65.06
20-Day Moving Average 61.77
10-Day Moving Average 62.12
Average True Range 2.99
ADX 8.7
+DI 22.18
-DI 18.81
Chandelier Exit (Long, 3 ATRs ) 56.24
Chandelier Exit (Short, 3 ATRs ) 67.29
Upper Bollinger Band 64.21
Lower Bollinger Band 59.33
Percent B (%b) 0.86
BandWidth 7.89
MACD Line -0.43
MACD Signal Line -0.85
MACD Histogram 0.4212
Fundamentals Value
Market Cap 2.28 Billion
Num Shares 35.8 Million
EPS -7.54
Price-to-Earnings (P/E) Ratio -8.42
Price-to-Sales 0.00
Price-to-Book 5.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 66.59
Resistance 3 (R3) 66.54 65.46 66.08
Resistance 2 (R2) 65.46 64.67 65.48 65.91
Resistance 1 (R1) 64.48 64.19 63.94 64.54 65.74
Pivot Point 63.40 63.40 63.13 63.43 63.40
Support 1 (S1) 62.43 62.62 61.89 62.48 61.28
Support 2 (S2) 61.35 62.13 61.37 61.11
Support 3 (S3) 60.37 61.35 60.94
Support 4 (S4) 60.43